Swedish Orphan Biovitrum AB (publ) B6E-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 06/11/21 CEST
15.28quote price arrow up+0.23 (+1.49%)
52 week range
12.48 - 22.78

...

Loading . . .
  • Open15.35
  • Day High15.35
  • Day Low15.28
  • Prev Close15.06
  • 52 Week High22.78
  • 52 Week High Date09/23/20
  • 52 Week Low12.48
  • 52 Week Low Date05/06/21

Key Stats

  • Market Cap5,550.35M
  • Shares Out294.9M
  • 10 Day Average Volume743.75
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-5.21

KEY STATS

  • Open15.35
  • Day High15.35
  • Day Low15.28
  • Prev Close15.06
  • 52 Week High22.78
  • 52 Week High Date09/23/20
  • 52 Week Low12.48
  • 52 Week Low Date05/06/21
  • Market Cap5,550.35M
  • Shares Out294.9M
  • 10 Day Average Volume743.75
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-5.21

RATIOS/PROFITABILITY

  • EPS (TTM)0.91
  • P/E (TTM)16.79
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Swedish Orphan Biovitrum AB (publ)

There is no recent news for this security.

Profile

MORE
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within...
Hakan Bjorklund Ph.D.
Non-Executive Chairman
Guido Oelkers
President
Henrik Stenqvist
Chief Financial Officer
Anne De Jonge Schuermans Ph.D.
Chief Technology Officer
Torbjorn Hallberg
General Counsel
Address
Tomtebodavagen 23A
Solna
112 76
Sweden